Summary: Joint modelling is increasingly popular for investigating the relationship between longitudinal and timeto-event data. However numerical complexity often restricts this approach to linear models for the longitudinal part.
Introduction
The field of joint modeling, which aims to characterize the relationship between longitudinal biomarkers and a time-to-event, has received a lot of attention from biostatisticians in the last decade (Tsiatis and Davidian, 2004; Rizopoulos et al., 2009; Wu et al., 2011) . Moreover large efforts have been made to reach out beyond the academic community and packages in R or codes and macro in SAS are now available (Guo and Carlin, 2004; Rizopoulos, 2010; Garcia-Hernandez and Rizopoulos, 2015) . However a major limitation of these tools is that they essentially rely on linear models for the longitudinal part (Tsiatis and Davidian, 2004; Rizopoulos, 2012; Asar et al., 2015) . Although these models are often sufficient to describe sparse longitudinal data, such as those obtained in epidemiological studies, they may not be appropriate to describe the kinetics of frequently sampled markers such as those obtained in clinical trials for treatment evaluation. In this context, nonlinear mechanistic models, for instance based on ordinary differential equations (ODEs), may be necessary to characterize the dynamic changes in the longitudinal markers but the difficulty to calculate the likelihood in nonlinear mixed effect models (NLMEM) complicates considerably the use of these models. In the last years, several stochastic methods have been developed to propose efficient algorithms for inference in NLMEM (Kuhn and Lavielle, 2005; Plan et al., 2012) .
One of them is the Stochastic Approximation Expectation-Maximization (SAEM) algorithm (Delyon et al., 1999) . As in other EM algorithms, the algorithm is an iterative process where each iteration is divided into a step where the complete likelihood conditional on observations is calculated (E-step), and a step where the complete likelihood is maximized (M-step). In addition, in the SAEM algorithm, the E-step is divided into two parts: a simulation of individual parameters using a Markov Chain Monte Carlo (MCMC) algorithm (S-step), and then a calculation of the expected likelihood using a stochastic approximation (A-step).
to the context of joint models and was shown by simulation to provide precise estimates when the longitudinal marker was defined by a NLMEM (Mbogning et al., 2015; Desmée et al., 2015) .
Here we applied this approach to characterize, on real data, the relationship between the kinetics of the Prostate-Specific Antigen (PSA) and survival in metastatic CastrationResistant Prostate Cancer (mCRPC) using data from a phase 3 clinical trial (Tannock et al., 2013) . In this context of patients with advanced disease, the incidence of death is high and the PSA kinetics is closely monitored after treatment initiation to rapidly detect a breakthrough in PSA and propose rescue strategies. Thus, unlike studies where long-term PSA levels can be described by linear models (Proust-Lima et al., 2008) here, the rapid changes in PSA levels require dynamical nonlinear models. Similarly to what is done to characterize the effect of an anti-viral treatment on a pathogen (Perelson and Guedj, 2015) , the PSA kinetics can be schematically viewed as a dynamic interaction between the chemotherapy and the process of production and elimination of cancer cells (Seruga, Ocana, and Tannock, 2011) .
This interaction can naturally be modeled using a system of nonlinear ODEs where both parameters and processes have a biological interpretation. Here, we aimed to show how a mechanistic joint approach can be used to characterize the relationship between the nonlinear kinetics of a biomarker and the time-to-death in the context of treatment evaluation.
The outline is as follows: in Section 2, we introduce the clinical data and the methods used to characterize the relationship between PSA kinetics and survival. In Section 3, we show how to construct and evaluate a joint model in the context of a mCRPC clinical trial. Lastly, in section 4, we conclude by pointing out the advantages and the limits of this approach.
Material and Methods

Description of the Data
We analyzed the data of 598 men with metastatic Castration-Resistant Prostate Cancer (mCRPC) treated with docetaxel and prednisone, the first-line reference chemotherapy, which constituted the control arm of a phase 3 clinical trial (Tannock et al., 2013) . In the protocol, PSA had to be measured within 8 days before treatment initiation, every 21 days during treatment and then every 84 days after treatment. Baseline available covariates were body size, age, race and time elapsed since hormone therapy. Two patients had no PSA measurement and were not included in the analysis.
For the sake of internal validation, the dataset was randomly split into a training and a validation dataset of 400 and 196 patients, respectively. In the training dataset, 6,627 PSA measurements were collected, among which 1,385 (20.9%) were pre-treatment and 3,934 (59.4%) were on treatment. The median [minimum ; maximum] otherwise, all results given below are obtained using the training dataset only.
Mechanistic PSA Kinetic Model
In this model (Figure 1 ), PSA is produced by two types of cells, namely treatment-sensitive cells (S) and treatment-resistant cells (R) (Seruga et al., 2011) . In absence of treatment, sensitive and resistant cells proliferate with rates α S and α R , respectively, and are eliminated with a similar rate d. The total number of sensitive and resistant cells is limited by a saturation term, noted N max . Mutations from S to R and from R to S occur with an identical rate, noted g. PSA is secreted by both treatment-sensitive and -resistant cells with a rate p and is cleared from the blood with a rate δ.
The associated system of ordinary differential equations (ODEs) is: 
Then one can obtain after few calculations on equations (1):
Time t = 0 indicates the beginning of treatment that has a constant and non-null effectiveness against the treatment-sensitive cells (ε > 0) while it has no efficacy against resistant cells. Two mechanisms of actions for docetaxel were considered (Herbst and Khuri, 2003; Petrylak, 2005) : it can either inhibit angiogenesis (i.e., decreases the cancer cells proliferation from α S before treatment initiation to α S × (1 − ε) afterwards) or increase cell apoptosis (i.e., stimulates the cancer cells elimination from d before treatment initiation to d × (1 + ε) afterwards).
[ Figure 1 about here.]
The following reparameterizations were done to improve the model identifiability. First since before treatment initiation PSA increased, the proliferation rate of sensitive cells is necessarily larger than the apoptosis rate (α S > d). Second after treatment initiation, no patient achieved a sustained low level of PSA, which means that the proliferation rate of resistant cells is also larger than the apoptosis rate (
For the sake of parameter identifiability, we fixed δ to 0.23 day −1 , corresponding to a PSA half-life in blood of about 3 days (Ruffion, Rebillard, and Grima, 2005) while p and g were determined by a sensitivity analysis (see Web Appendix A).
Finally, the mathematical model for PSA kinetics was defined by the vector parameter:
Statistical Model for PSA Measurements
Nonlinear mixed-effect models (NLMEM) were used to analyze all the longitudinal PSA measurements (before, during and after treatment).
Let N be the number of patients and y i = (y i1 , . . . , y in i ) the vector of observations in patient i, where y ij is the observed Naperian logarithm of PSA+1 for the patient i, i = 1, . . . , N , at time t ij , j = 1, . . . , n i . A constant error model is assumed on the logarithm of PSA+1:
where ψ i is the vector of the individual parameters, P SA(t ij , ψ i ) is given by the system of ODEs (1) and e ij is the residual Gaussian error of mean 0 and variance σ 2 . ψ i is decomposed as a vector of fixed effects µ representing median parameters of the population and random effects η i specific for each individual. It is assumed that η i ∼ N (0, Ω 2 ) with
We assumed log-normal distribution for α S , PSA b and N max and logit-normal distribution for RF and RE. Regarding ε, we used a logit-normal distribution when an effect in blocking cell proliferation was evaluated and a log-normal distribution when an effect of treatment in enhancing cell death was evaluated (see section 2.2).
Characterization of the Relationship between PSA Kinetics and Survival
Let X i and C i denote the time-to-death and the censoring time, respectively, for patient
The time-to-death was modeled using a parametric risk-proportional model assuming a Weibull function for the baseline hazard function: for t 0,
where PSA(t, ψ i ) = {P SA(s, ψ i ); 0 s < t} denotes the history of the true unobserved longitudinal process up to t, h 0 is the Weibull baseline hazard function
is the vector of coefficients associated with the vector of baseline covariates w i and β is the vector of coefficients associated with the ODE model outputs f (t, ψ i ) (Eq. 1).
The following models for the relationship between survival and PSA kinetics were considered:
• Current S and R: f (t, ψ i ) = (log(S(t, ψ i )), log(R(t, ψ i ))). In this model β has two compo-
Of note the last three models exploit the mechanistic nature of the model as they relate to quantities that are not observed.
Maximum Likelihood Estimation
The log-likelihood for subject i is given by:
where θ = (µ, Ω, σ, λ, k, γ, β) is the vector of parameters to estimate, p(y i |η i ; θ) is the probability density function of the longitudinal observations conditionally on the random
is the probability density function of the random effects.
The likelihood was maximized using the SAEM algorithm (Delyon et al., 1999; Kuhn and Lavielle, 2005) implemented in Monolix version 4.3.2. The likelihood was estimated by Importance Sampling with a Monte-Carlo size of 200,000 to ensure efficient precision. SAEM was run using one chain after checking that using 3 chains gave similar results (Vigan et al., 2014) . All calculations were performed in a i7 64bits 3.33 GHz.
Model Selection and Evaluation
We first selected the model for the longitudinal data using only longitudinal data. For each couple of parameters (p, g) explored in the sensitivity analysis (Web Appendix A), the two possible mechanisms of action of treatment were tested and only the model giving the lowest Bayesian Information Criterion (BIC) was retained.
Next the selection of the joint model was based on the BIC (Park and Qiu, 2014) . (Rizopoulos, 2012; Sène, Bellera, and Proust-Lima, 2014) . In addition to the residuals and in order to evaluate the overall prediction for the survival, the mean survival curve, defined by S(t) = 1 N N i=1 S i (t|P SA(t,ψ i );θ) was calculated and compared to the Kaplan-Meier curve.
In order to evaluate the ability of the model to predict the survival in a different dataset, the mean survival curve was also calculated in the validation dataset. For that purpose, population parameters were fixed to the values found in the training dataset (e.g.,θ) and individual parameters ψ i were estimated from the EBEs. Of note the time-to-death in the validation dataset was not used to estimate the mean survival curve of this dataset.
Lastly, the parametric assumption for the baseline hazard function was relaxed and spline functions for the baseline hazard h 0 , namely piecewise constant, linear and restricted cubic, were tested. More details can be found in the Web Appendix B.
Results
Model Selection
A model assuming an effect of docetaxel on cell angiogenesis systematically provided a better fit to the longitudinal data than a model assuming an effect on cell apoptosis. Therefore only the results of the model with an effect on cell angiogenesis will be discussed below. The values for the PSA production rate and for the mutation rate, noted p and g, respectively, were fixed to 20 ng.day −1 and 10 −7 day −1 after the sensitivity analysis study (see Web Appendix A). None of the baseline covariates had a p-value lower than 0.2 in univariate analysis and therefore none of them were tested in the joint model (γ = 0).
[ Table 1 about here.]
Parameter estimates obtained with the 8 candidate joint models are summarized in Table 1. PSA kinetic parameters were largely insensitive to the choice of the survival part of the model.
In all cases they were precisely estimated with relative standard error smaller than 8% for both fixed effects and variance components. In particular the treatment effect in blocking angiogenesis, ε, was consistently estimated to about 43% (p < 10 −15 by likelihood ratio test) and the fitness of resistant cells was close to that of sensitive cells (RF = 99.98%). The model using the current PSA value outperformed all models relying on PSA in terms of BIC. Surprisingly the models based on the current PSA slope and on the cumulative PSA (Area under PSA), did not lead to a large improvement in the BIC compared to the No Link model, i.e., the parametric Weibull model with no effect of PSA on survival.
One of the advantages of mechanistic models is that unobserved quantities can also be In order to evaluate the capability of the model to capture the fact that PSA value at treatment initiation is associated with survival, we also compared the mean survival curves and the Kaplan-Meier curves according to the initial PSA value, P SA 0 . Interestingly the model still well captured the survival function in the patients with P SA 0 40 or 40 < P SA 0 140. However we note that the model tended to underestimate the survival in patients with P SA 0 140, i.e., patients with very high baseline PSA values, but the mean survival curve remained included in the Kaplan-Meier 95% confidence interval.
[ Figure 4 about here.]
Finally we applied the joint model on the 196 mCRPC patients from the validation dataset.
For that purpose, we fixed the population parameters to the values found in the training dataset and we calculated the EBEs for each patient (see Section 2.6). In other words, the individual trajectories for both PSA and the hazard function in a patient were calculated using only the observed PSA measurements of that patient and the information on the vital status in this dataset was not used. As can be seen in Figure 5 , the Kaplan-Meier curve in the training and in the validation dataset did not exactly overlay and there was a 58 days difference in the median survival between the two datasets. In spite of this discrepancy, the mean survival curve well fitted the Kaplan-Meier curve of the validation dataset, showing that the inclusion of the individual PSA kinetics was sufficient to correctly predict the survival in this dataset.
[ Figure 5 about here.]
All data and codes needed to reproduce the results, evaluate the residuals and generate the figures are available as supplementary materials with a README file.
Discussion
A mechanistic joint model was proposed to study the relationship between survival and longitudinal data described by a system of nonlinear ODEs. Unlike what is done in virology and bacteriology, the field of mechanistic model for treatment evaluation in oncology is still in its infancy. Here, following the efforts of other groups that aimed to develop cancer models that can be used for clinical purposes (Ribba et al., 2014) , we showed that mechanistic joint models could be used for prediction of time-to-event in clinical trials. Our model allowed to capture a variety of patterns in PSA kinetics observed before, during and after chemotherapy.
Further the model predicted that two quantities, namely docetaxel-sensitive and resistant cancer cells, may have a large impact on survival. Of note these two quantities were not observed, and the only observed quantity was the PSA value, which was assumed to be proportional to the total number of cancer cells. The kinetics of docetaxel-resistant cells had a larger impact on survival than the kinetics of treatment-sensitive cells. Since the kinetics of resistant cells drives the increase in PSA levels on the long-run, our prediction is consistent and expands the observation that the final tumor growth rate is highly predictive of the time-to-death (Stein et al., 2008) . The relevance of the model was further reinforced by the fact that it could be used to predict the survival curve of the 196 patients that had not been used for model building. By including only the information on PSA and ignoring the information on survival in these patients, the model prediction well matched with the Kaplan-Meier curve observed in these patients.
One of the main advantages of mechanistic joint model is that parameters have a biological interpretation. Therefore putative scenarios can be performed to anticipate the impact of changes in experimental settings. Here, for instance, one could evaluate by simulation the effect of a drug that could affect the resistant cells, either by blocking the proliferation of resistant cells or by having a complementary mechanism of action. Further, this approach could be useful to guide and design cancer clinical trials by using model predictions (such as here S and R) as surrogate markers and thus possibly reduce the follow-up time or the number of patients needed to assess treatment efficacy or to compare different treatment strategies.
However, this will require to pursue the development of these models and to integrate data that are rarely collected or analyzed longitudinally such as the count of circulating tumor cells (CTC) (Wilbaux et al., 2015) , the size of the tumors and/or drug pharmacokinetics. ODE models are particularly suitable for that purpose since correlations between the biomarkers can be naturally taken into account through their mechanistic interactions. Obviously these models will need to be validated internally but also externally, which was not done here, to assess their predictive ability in a different context.
However the complexity of these models comes with a cost. In terms of feasibility these models require frequent sampling longitudinal measurements to characterize the kinetics.
This limits their use in the context of epidemiological studies where usually large cohorts of patients are followed with sparse measurements. Although SAEM algorithm, unlike other methods such as adaptive Gaussian quadratures (Guedj et al., 2011; Prague et al., 2013) , can deal with a large number of random effects (Lavielle et al., 2011) , it remains time-consuming.
Further, in our case and in spite of this computation time, the calculation of the likelihood was still associated with a non-negligible standard errors, making the use of these models not reliable to identify small effects. Lastly, it remains to be demonstrated that such mechanistic joint models can be used in practice for dynamic predictions, i.e., to improve the prediction of an individual patient followed prospectively (Rizopoulos, 2011 ).
In conclusion, we used a novel feature of SAEM algorithm of Monolix that allows joint modelling with a longitudinal process described by ODEs to develop a mechanistic joint model for PSA kinetics and time-to-death. This model sheds a new light on the relationship between PSA and death in mCRPC patients and this approach opens the way for the use of more complex and physiological models to improve treatment evaluation and prediction.
Supplementary Materials
Web Appendices referenced in Sections 2 and 3, as well as training dataset, MLXTRAN code, R codes and a README file are available with this paper at the Biometrics website on Wiley Online Library. Figure 1 . Schema of the secretion of PSA by sensitive (S) and resistant (R) cells. PSA is expressed in ng.mL −1 and S and R in mL −1 . In absence of treatment, α S and α R are the rates of S and R proliferation (day −1 ), respectively, d the rate of S and R elimination (day −1 ), g is the mutation rate (day −1 ), p the rate of PSA secretion by S and R (ng.day −1 ) and δ the rate of PSA elimination (day −1 ). Treatment can inhibit S cells proliferation (big cross) or stimulate S cells elimination (big arrow) with the constant effectiveness ε. This figure appears in color in the electronic version of this article. Table 1 Goodness-of-fit statistics (standard error) and parameters estimates (relative standard error (%)) of PSA kinetics and survival in the 400 patients of the training dataset for the 8 joint models. 14508 (7) 14486 (7) 14350 (7) 14485 (7) 14479 (7) 14471 (7) 14334 (7) 14326 (8) BIC 14598 (7) 14582 (7) 14446 (7) 14581 (7) 14575 (7) 14567 (7) 14430 (7) 14421 (8) α S (day 
